Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Swallow a sponge to check for esophageal cancer?

NCT ID NCT07490340

Diagnosis Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called Endosign, which is a sponge on a string that patients swallow to collect cells from the esophagus. The goal is to see if this simple, non-sedation method can provide good enough samples to replace regular endoscopies for monitoring Barrett's esophagus, a condition that can lead to esophageal cancer. The trial involves 60 adults with Barrett's esophagus, both with and without early cancer changes. If it works, it could make surveillance much easier and cheaper.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endosign (sponge-on-a-string sampling device)
What this could lead to
If successful, this could offer a less invasive, cheaper way to monitor Barrett's esophagus, potentially catching esophageal cancer earlier.
What could go wrong
This is a small pilot study (60 people) testing only sample quality, not long-term outcomes. The device may not reliably replace endoscopy, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

: non dysplastic and dysplastic BE patients who will undergo endoscopy for surveillance or treatment

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Patients age: ≥ 18 years * BE with a maximal extent of ≥4cm * Willingness to undergo an esophagogastroduodenoscopy with sedation * Cohort 1: Patients referred for endoscopic treatment of HGD or EAC * Cohort 2: Patients with known BE without a diagnosis of HGD or EAC in the previous 18 months, undergoing endoscopic surveillance * Ability to give written, informed consent and understand the responsibilities of participation Exclusion Criteria: * Patients within eight weeks after endoscopy with biopsies and/or ER * History of esophageal or gastric surgery other than Nissen fundoplication * History of esophageal ablation or dilation therapy * Presence of esophageal varices and/or suspected portal hypertension * Dysphagia/ swallowing disorders * Pregnancy * Patients with known or suspected anatomical abnormalities of the esophagus or stomach * Patients taking anti-thrombotic drugs that cannot be temporarily discontinued * Subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Barrett esophagus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus Barrett esophagus disease esophageal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Barrett esophagus Diagnosis Esophageal adenocarcinoma

Contacts and locations

Locations

  • Amsterdam University Medical Centre, loc. VUmc

    Amsterdam, North Holland, 1081HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.